Evidence map›Paper›PMID 31787498›Full record

ArticleJournal of stroke and cerebrovascular diseases : the official journal of National Stroke Association2020

Poor Outcomes Related to Anterior Extension of Large Hemispheric Infarction: Topographic Analysis of GAMES-RP Trial MRI Scans.

Seyedmehdi Payabvash, Guido J Falcone, Gordon K Sze, Abhi Jain, Lauren A Beslow, Nils H Petersen, Kevin N Sheth, W Taylor Kimberly

Registry-linked trialOpen access · greenAbstract readComparative StudyMulticenter Study
In one paragraph

Article in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01794182 (A Randomized, Multi-Center, Prospective, Double Blind, Phase II Trial of RP- 1127), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01794182 phase2completednot on this map

A Randomized, Multi-Center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema

TypeinterventionalSponsorRemedy Pharmaceuticals, Inc.Ran2013 to 2016Enrolled86ConditionsIschemic Stroke, Malignant EdemaArmsGlyburide for Injection, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Sulfonylurea drugs for people with severe hemispheric ischemic stroke.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Seyedmehdi PayabvashDivision of Neuroradiology, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.
Guido J FalconeDivision of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut.
Gordon K SzeDivision of Neuroradiology, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.
Abhi JainCollege of Medicine, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania.
Lauren A BeslowDivision of Neurology, Children's Hospital of Philadelphia, Departments of Neurology and Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Nils H PetersenDivision of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut.
Kevin N ShethDivision of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut. Electronic address: kevin.sheth@yale.edu.
W Taylor KimberlyDivision of Neurocritical Care and Emergency Neurology, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.
Yale University · USChildren's Hospital of Philadelphia · USMassachusetts General Hospital · USPhiladelphia College of Osteopathic Medicine · US

Funding

Yale Study Support Suite (YES3): Dashboard and Web Portal Software Supporting Research Workflow through integrated, customizable REDCap External ModulesP30AG021342 · NIA · YALE UNIVERSITY · PI Albert C Shaw · 2002 to 2026
$37.9M
Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE)U01NS106513 · NINDS · YALE UNIVERSITY · PI Hooman Kamel, Kevin Navin Sheth · 2019 to 2026
$20.6M
The Recovery in Stroke Using PAP (RISE UP) StudyR01NR018335 · NINR · YALE UNIVERSITY · PI REDEKER, NANCY S, SHETH, KEVIN NAVIN · 2019 to 2023
$3.4M
Southern New England Partnership In Stroke Research, Innovation and Treatment (SPIRIT)U24NS107215 · NINDS · YALE UNIVERSITY · PI MARK Jay ALBERTS, Karen L Furie · 2018 to 2026
$3.0M
Metabolomic predictors of stroke in REGARDSR01NS099209 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI KIMBERLY, WILLIAM TAYLOR · 2017 to 2021
$2.4M
Improved glyburide therapy via acid- triggered release functional nanoparticles and therapeutic imagingR01NS110721 · NINDS · YALE UNIVERSITY · PI SHETH, KEVIN NAVIN, ZHOU, JIANGBING · 2019 to 2023
$1.9M
Yale Clinical Site: Investigations For Improved Neurological Treatments at Yale (INFINITY)U24NS107136 · NINDS · YALE UNIVERSITY · PI SHETH, KEVIN NAVIN, SPUDICH, SERENA S · 2018 to 2022
$1.7M
Metabolomic analysis of acute stress hyperglycemia in ischemic strokeK23NS076597 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI KIMBERLY, WILLIAM TAYLOR · 2011 to 2015
$959k
Intensive Blood Pressure Reduction in Deep Intracerebral HemorrhageR03NS112859 · NINDS · YALE UNIVERSITY · PI FALCONE, GUIDO JOSE, SHETH, KEVIN NAVIN · 2019 to 2020
$84k
NIA NIH HHS K76 AG059992NIA NIH HHS P30 AG021342NINDS NIH HHS K23 NS076597NINDS NIH HHS R01 NS099209NINDS NIH HHS R01 NS110721NINDS NIH HHS U01 NS106513NINDS NIH HHS U24 NS107136NINDS NIH HHS U24 NS107215NINR NIH HHS R01 NR018335
6 · The paper itself

Abstract

backgroundWe aimed to assess the correlation of lesion location and clinical outcome in patients with large hemispheric infarction (LHI).

methodsWe analyzed admission MRI data from the GAMES-RP trial, which enrolled patients with anterior circulation infarct volumes of 82-300 cm

resultsWe included 83 patients with known 3-month modified Rankin scale (mRS). In voxel-wise analysis, there was significant correlation between admission infarct lesions involving the anterior cerebral artery (ACA) territory and its middle cerebral artery (MCA) border zone with both higher 3-month mRS and post-stroke day 3 and 7 National Institutes of Health Stroke Scale (NIHSS) total score and arm/leg subscores. Higher NIHSS total scores from admission through poststroke day 2 correlated with left MCA infarcts. In multivariate analysis, ACA territory infarct volume (P = .001) and admission NIHSS (P = .005) were independent predictors of 3-month mRS. Moreover, in a subgroup of 36 patients with infarct lesions involving right MCA-ACA border zone, intravenous (IV) glibenclamide (BIIB093; glyburide) treatment was the only independent predictor of 3-month mRS in multivariate regression analysis (P = .016).

conclusionsAnterior extension of LHI with involvement of ACA territory and ACA-MCA border zone is an independent predictor of poor functional outcome, likely due to impairment of arm/leg motor function. If confirmed in larger cohorts, infarct topology may potentially help triage LHI patients who may benefit from IV glibenclamide. CLINICAL

trial registrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT01794182.

Indexed as

Diffusion Magnetic Resonance ImagingAdministration, IntravenousAgedAnterior Cerebral ArteryCerebrovascular CirculationCerebrumClinical Trials as TopicClinical Trials, Phase II as TopicDisability EvaluationExtremitiesFemaleGlyburideHumansHypoglycemic AgentsInfarction, Anterior Cerebral ArteryInfarction, Middle Cerebral ArteryGlyburideHypoglycemic Agentsglibenclamideglyburideinfarct locationIschemic strokelesion topographymalignant infarction

Identifiers

PMID31787498
PMCPMC8820410
OpenAlexW2989813765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.